Bianchi Porro G, Lazzaroni M, Barbara L, Corinaldesi R, Dal Monte P R, D'Imperio N, Mazzacca G, D'Arienzo A, Cheli R, Bovero E
Gastrointestinal Unit, Ospedale L. Sacco, Milan, Italy.
Scand J Gastroenterol. 1988 Dec;23(10):1232-6. doi: 10.3109/00365528809090196.
One hundred patients were entered into a double-blind, double-dummy comparison of tripotassium dicitrate bismuthate (TDB) versus ranitidine, to evaluate short-term healing rates, and successfully healed patients were then entered into a follow-up phase to observe relapse rates. At 4 weeks 84% of patients treated with TDB and 68% of those treated with ranitidine had healed. At 8 weeks these figures had risen to 96% and 90%, respectively (p = NS). After a year's follow-up study 84% of patients healed initially with ranitidine had relapsed, whereas in the case of patients healed initially with TDB the relapse rate was 67% (p less than 0.05). The results confirm that in the short term, TDB is as effective as ranitidine, whereas the significantly better protection against relapse offered by TDB compared with ranitidine underlines the importance of restoring mucosal defence, an approach that to date has been somewhat overlooked.
100名患者参与了枸橼酸铋钾（TDB）与雷尼替丁的双盲、双模拟对照试验，以评估短期愈合率，随后将成功愈合的患者纳入随访阶段以观察复发率。4周时，接受TDB治疗的患者中有84%愈合，接受雷尼替丁治疗的患者中有68%愈合。8周时，这些数字分别升至96%和90%（p=无显著性差异）。经过一年的随访研究，最初用雷尼替丁治愈的患者中有84%复发，而最初用TDB治愈的患者复发率为67%（p<0.05）。结果证实，短期内，TDB与雷尼替丁效果相当，而与雷尼替丁相比，TDB对复发的显著更好的预防作用凸显了恢复黏膜防御的重要性，而这种方法迄今为止在一定程度上被忽视了。
